Business Information
The group's principal activity is to discover, develop and commercialize drugs for the treatment of chronic inflammatory diseases. These drugs are used in the treatment of atherosclerosis, heart disease, asthma, organ transplant rejection and rheumatoid arthritis. Its main products, the agi-1067 is an oral drug to benefit patients with coronary artery disease, agix-4207 i.v. To treat rheumatoid arthritis patients in whom the rapid attainment of target drug levels in the blood is desirable, agix-4207 for rheumatoid arthritis and agi-1096 designed to both diminish the organ transplant response to inflammation and to directly protect the blood vessels to the transplanted organ through its v-protectanttm activity . Group depends on a third party manufacturer for the supply of agi-1067 bulk drug substance and formulated drug products. Oxykine, design, agi and aatherogenics are the registered trademarks of the group.
|
|
Name |
Title
|
Email
|
| Michael Henos | Chmn. | N/A | | Russell Medford | Dir., Scientific Co - Founder, CEO, Pres. | N/A | | Charles Montgomery | Sr. VP - Business Development, Alliance Management | N/A | | Joseph Gaynor | Sr. VP, General Counsel | N/A | | Mark Colonnese | Exec. VP - Commercial Operations, CFO | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 31,675 | (67,322) | | 2005 | N/A | (82,554) | | 2004 | N/A | (69,589)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
